Corrado Advisors’s Celldex Therapeutics CLDX Stock Holding History

Corrado Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-33	Closed	-$1.47K	–	165
2022 Q4	$1.47K	Buy	+33	New	+$1.18K	﹤0.01%	347

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Corrado Advisors's CLDX Position: Q1 2023 in Review

Corrado Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 33 shares — an estimated $1.47K sold.

Corrado Advisors first reported a position in CLDX in Q4 2022 and held it in 1 quarter. The position peaked at $1.47K in Q4 2022. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

Corrado Advisors reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
Corrado Advisors sold 33 Celldex Therapeutics shares in Q1 2023, an estimated $1.47K.
Corrado Advisors first reported a position in Celldex Therapeutics in Q4 2022 and held it in 1 quarter.
Corrado Advisors's Celldex Therapeutics position peaked at $1.47K in Q4 2022.
161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on Corrado Advisors's 13F filing for Q1 2023, filed 3 May 2023.